Figure 6.
Treatment with BD750-treated DC ameliorates EAE. C57BL/6 mice were immunized with MOG35-55 peptide in CFA and PTX. (A) The mice were randomized and treated intravenously with 20 μM BD750 pretreated DC (12 h) loaded with MOG35-55 on d 7, 11 and 15 post the first PTX injection. Data are shown as the mean ± SEM of each group (n = 8 per group). *P < 0.05 versus the PBS group. (B) The EAE mice were treated intravenously with 20 μM BD750-treated DCs loaded with or without MOG35-55 on d 7, 11 and 15 post the first PTX injection. Data are shown as the mean ± SEM of each group (n = 8 per group). *P < 0.05 versus the DC (20 μM BD750) without MOG35-55 loading group. (C) The EAE mice were treated intravenously with 20 μM BD750-treated DCs loaded with MOG35-55 on d 7, 11 and 15 or delayed on 19, 23 and 27 d or earlier on d –2, 2 and 6 post the first PTX injection. Data are shown as the mean ± SEM of each group (n = 8 per group). *P < 0.05 versus the tolDC intravenous (dpi 19, 23 and 27) group. (D) The EAE mice were treated intravenously with 20–M BD750-treated DC loaded with MOG35-55 on d 7, 11 and 15 post induction only for 1–2 times. Data are shown as the mean ± SEM of each group (n = 8 per group). *P < 0.05 versus the tolDC intravenous (dpi 7) group. The dynamic progression of EAE in individual groups of mice was monitored daily by two researchers without knowing the groups in a blinded manner, and some mice from some groups of mice were euthanized at 22 d post induction for analysis of inflammation and demyelination in the spinal cord tissues. (E) Histological examinations. Arrows indicate inflammatory infiltrates. Scale bar, 100μm (magnification 100 ×).